Developer docs
API playgroundTry for free, no card

Search company profiles

EpiCypher

Full company profile

uuid0000hrq

Namestring
EpiCypher
Legal namestring
EPICYPHER, INC.
Websiteurl
epicypher.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

EpiCypher is a privately held biotechnology company founded in 2012 and headquartered in Research Triangle Park, Durham, North Carolina. The company develops and manufactures products and tools for epigenetics and chromatin biology research, serving academic and research institutions, pharmaceutical companies, and biotech firms. Its customer base is organized horizontally around chromatin biology use cases including chromatin profiling, gene regulation studies, disease mechanism investigation, and epigenomics-based drug discovery.

The company's core technology is the CUTANA platform, which encompasses CUT&RUN and CUT&Tag chromatin profiling assays that map histone post-translational modifications and chromatin-associated proteins with higher sensitivity and lower input requirements than traditional ChIP-seq. Recent extensions include the Fiber-seq Kit (a multiomic long-read sequencing assay licensed exclusively from the Altius Institute for Biomedical Sciences that simultaneously profiles chromatin accessibility, DNA methylation, protein footprints, and genetic variants at single-molecule resolution), the meCUT&RUN Kit for DNA methylation profiling using engineered MeCP2, the SNAP-Certified Antibody and spike-in control system for assay validation, over 190 unique nucleosome products with defined PTM states, EpiDyne chromatin remodeling assay substrates, and the CUTANA Cloud bioinformatics platform. EpiCypher holds granted patents on CUT&Tag in the US, EU, Japan, and China, and has multiple pending applications around Fiber-seq.

EpiCypher generates revenue through product sales (kits priced $145-$2,395, antibodies $110-$545, recombinant and designer nucleosomes $425-$575), custom laboratory services (CUT&RUN, Fiber-seq, DNA methylation sequencing, custom nucleosome development), and usage-based bioinformatics credits on CUTANA Cloud ($20-$40 per credit). Distribution is hybrid: direct-to-consumer e-commerce and quote-based sales in the US, plus international distributors and a recently expanded strategic partnership with New England Biolabs covering international markets. The company maintains a presence at industry conferences, runs webinars and a co-authored publication program, and operates dedicated support channels for academic and industrial customers.

Short descriptiontext

EpiCypher is a privately held biotechnology company founded in 2012 in Durham, North Carolina that develops chromatin mapping assays, nucleosome reagents, and bioinformatics tools for epigenetics research, serving academic, pharmaceutical, and biotech customers globally through direct sales and distributor partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chromatin mapping kits, epigenetics research tools, DNA methylation assays, recombinant nucleosome products, chromatin profiling reagents
Industry4 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Epigenetics Research Tools
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Product Sales - Kits and Reagents
TypeOne Time License
Description

Sale of chromatin mapping assay kits, nucleosome products, antibodies, and reagents directly through the company website and via international distributors

epicypher.com
2Custom Services
TypeProfessional Services
Description

Laboratory services including CUTANA CUT&RUN Services, Fiber-seq Assay Services, DNA Methylation Sequencing Services, and Custom Nucleosome Development Services

epicypher.com
3Cloud Bioinformatics Credits
TypeUsage Based
Description

Pay-as-you-go credits for CUTANA Cloud data analysis platform, with tiered pricing based on volume

epicypher.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Pricing details6 tiers
1CUTANA Fiber-seq Kit - 8 Reactions: $695.00, 24 Reactions: $1,795.00
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Patent-pending Fiber-seq kit for long-read chromatin mapping. Prices are for US customers. Storage stable for 6 months upon receipt.

epicypher.com
2CUTANA CUT&Tag Kit v4 - 24 Reactions: $1,295.00, 48 Reactions: $2,395.00
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Includes all reagents from cells to sequencing libraries. Current promotional offer of 15% off using code CTK15 through August 31st for US customers.

epicypher.com
3meCUT&RUN Kit for DNA Methylation Sequencing: $685.00 (24 reactions)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

DNA methylation enrichment kit using engineered MeCP2 protein. Awarded 2025 Top Innovation in Lab Research Tools category.

epicypher.com
4CUTANA Cloud: $25 per credit (introductory), $20-$40 standard pricing
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Data analysis credits: 8-23 credits at $25 intro / $40 standard; 24-95 credits at $25 intro / $35 standard; 96-383 credits at $25 intro / $30 standard; 384+ credits at $20 standard. Introductory pricing valid through June 30th, 2026. First 300GB data storage free.

epicypher.com
5CUT&RUN Kits: $595-$945; SNAP-CUTANA K-MetStat Panel: $325; Antibodies: $110-$545
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Complete CUT&RUN and spike-in control products for chromatin mapping. Range includes various kit sizes and individual antibodies.

epicypher.com
6Recombinant Nucleosomes: $425-$575; Designer Nucleosomes (dNucs): $525-$575
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Over 190 unique nucleosome products available. Prices vary by modification type and biotinylation status. Custom nucleosome development services available upon request.

epicypher.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1CUTANA
Description

CUTANA is EpiCypher's flagship platform for chromatin mapping assays including CUT&RUN and CUT&Tag technologies.

epicypher.com
+4 more records
Core offering1 text field

EpiCypher develops, manufactures, and sells proprietary kits, reagents, and assays for chromatin mapping and epigenomics research, including CUTANA CUT&RUN, CUT&Tag, Fiber-seq, and meCUT&RUN kits, over 190 recombinant and modified nucleosome products, SNAP spike-in controls, SNAP-certified antibodies, and the CUTANA Cloud bioinformatics platform. The company also offers fee-for-service laboratory execution for chromatin profiling and custom nucleosome development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80% DNA methylation capture with input as low as 10,000 cells using meCUT&RUN
+3 more records
Product overview1 text field

EpiCypher offers a comprehensive portfolio of epigenetics research products centered on the CUTANA platform, including CUTANA CUT&Tag Kits (v4), CUTANA CUT&RUN Kits and Assays, Fiber-seq Kits for long-read sequencing, meCUT&RUN DNA Methylation Sequencing Kits, and Multiomic CUT&RUN assays. The company provides over 190 unique nucleosome products including recombinant, modified, mutant, and cell-derived nucleosomes with defined PTMs. Additional offerings include SNAP-Certified Antibodies, SNAP Spike-in Controls, EpiDyne Chromatin Remodeling Assays, and the CUTANA Cloud bioinformatics platform. EpiCypher also provides laboratory services including CUT&RUN Services, Fiber-seq Assay Services, DNA Methylation Sequencing Services, Custom Nucleosome Development, Captify Assay Services, and an FFPE Grant Program. The products work together as an integrated ecosystem where CUT&Tag and CUT&RUN assays generate data analyzed by CUTANA Cloud, while spike-in controls and nucleosomes enable workflow optimization and validation.

Product and service2 records
1CUTANA CUT&Tag Kit
CategoryChromatin profiling kit
Description

Complete solution for ultra-sensitive mapping of histone post-translational modifications featuring direct-to-PCR protocol, pAG-Tn5 tagmentation, and all reagents from cells to sequencing libraries.

2CUTANA CUT&RUN Assays
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-19
Description

Expanded strategic partnership where NEB distributes EpiCypher's genomic products in international markets. Partnership builds on prior collaboration and focuses on developing innovative technologies for gene regulation, chromatin biology, and disease mechanisms.

2Altius Institute for Biomedical Sciences
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-12
Description

EpiCypher licensed Fiber-seq technology from the Altius Institute for Biomedical Sciences. This exclusive licensing arrangement provides EpiCypher rights to commercialize the breakthrough single-molecule chromatin mapping technology.

pharmiweb.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-10-14
Description

Partnership announced alongside PacBio's Revio and Vega platform innovations to expand sample preparation and chromatin analysis capabilities. EpiCypher's Fiber-seq and chromatin mapping products integrate with PacBio's long-read sequencing platforms for enhanced epigenomics research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Active Motif is a direct competitor in chromatin and epigenetics research kits, including CUT&RUN and ChIP-seq reagents, antibodies, and nucleosomes sold to the same academic and pharma customer base as EpiCypher.

TypeDirect peer
Description

Diagenode offers CUT&RUN and CUT&Tag kits, antibody portfolios, and epigenetics services that directly compete with EpiCypher's CUTANA franchise, serving overlapping academic and translational customers.

TypeDirect peer
Description

CST provides CUT&RUN-validated antibodies and is a direct competitor in histone PTM reagents and chromatin profiling consumables, with overlapping SNAP-Certified-style antibody validation use cases.

TypeDirect peer
Description

Zymo Research sells DNA methylation and epigenetics kits (e.g., bisulfite conversion, Methylated DNA IP) that compete with EpiCypher's meCUT&RUN offering for the same DNA methylation research budgets.

TypeBroad incumbent
Description

NEB is both EpiCypher's international distribution partner and a broad incumbent in molecular biology reagents and enzymes, offering overlapping capabilities in nucleic acid processing and chromatin research tools.

TypeBroad incumbent
Description

Abcam is a broad incumbent supplying antibodies and reagent kits including histone PTM antibodies used in CUT&RUN/CUT&Tag, competing with EpiCypher's SNAP-Certified Antibody line for the same research budgets.

7Millipore Sigma
TypeBroad incumbent
Description

MilliporeSigma supplies a broad catalog of life science reagents, nucleosomes, and antibodies used in chromatin research, providing overlapping but less specialized offerings compared to EpiCypher's curated epigenetics portfolio.

TypeBroad incumbent
Description

Thermo Fisher offers broad life sciences reagents, instruments, and bioservices including chromatin immunoprecipitation and methylation products that compete indirectly with EpiCypher's kit and service portfolio.

TypeEmerging player
Description

Watchmaker Genomics is an emerging player in DNA sequencing library prep and molecular biology reagents with partial overlap to EpiCypher's library prep and enzyme product lines.

TypeEmerging player
Description

10x Genomics provides single-cell ATAC and multiome chromatin accessibility assays that serve the same single-cell chromatin profiling customer base as EpiCypher's CUTANA-based assays, representing an adjacent emerging competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EpiCypher

Epigenetics Research Toolsepicypher.com

EpiCypher is a privately held biotechnology company founded in 2012 in Durham, North Carolina that develops chromatin mapping assays, nucleosome reagents, and bioinformatics tools for epigenetics research, serving academic, pharmaceutical, and biotech customers globally through direct sales and distributor partnerships.

What EpiCypher does

EpiCypher is a privately held biotechnology company founded in 2012 and headquartered in Research Triangle Park, Durham, North Carolina. The company develops and manufactures products and tools for epigenetics and chromatin biology research, serving academic and research institutions, pharmaceutical companies, and biotech firms. Its customer base is organized horizontally around chromatin biology use cases including chromatin profiling, gene regulation studies, disease mechanism investigation, and epigenomics-based drug discovery.

The company's core technology is the CUTANA platform, which encompasses CUT&RUN and CUT&Tag chromatin profiling assays that map histone post-translational modifications and chromatin-associated proteins with higher sensitivity and lower input requirements than traditional ChIP-seq. Recent extensions include the Fiber-seq Kit (a multiomic long-read sequencing assay licensed exclusively from the Altius Institute for Biomedical Sciences that simultaneously profiles chromatin accessibility, DNA methylation, protein footprints, and genetic variants at single-molecule resolution), the meCUT&RUN Kit for DNA methylation profiling using engineered MeCP2, the SNAP-Certified Antibody and spike-in control system for assay validation, over 190 unique nucleosome products with defined PTM states, EpiDyne chromatin remodeling assay substrates, and the CUTANA Cloud bioinformatics platform. EpiCypher holds granted patents on CUT&Tag in the US, EU, Japan, and China, and has multiple pending applications around Fiber-seq.

EpiCypher generates revenue through product sales (kits priced $145-$2,395, antibodies $110-$545, recombinant and designer nucleosomes $425-$575), custom laboratory services (CUT&RUN, Fiber-seq, DNA methylation sequencing, custom nucleosome development), and usage-based bioinformatics credits on CUTANA Cloud ($20-$40 per credit). Distribution is hybrid: direct-to-consumer e-commerce and quote-based sales in the US, plus international distributors and a recently expanded strategic partnership with New England Biolabs covering international markets. The company maintains a presence at industry conferences, runs webinars and a co-authored publication program, and operates dedicated support channels for academic and industrial customers.

EpiCypher firmographics

Firmographics
Name
EpiCypher
Legal name
EPICYPHER, INC.
Website
https://epicypher.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
EpiCypher is a privately held biotechnology company founded in 2012 in Durham, North Carolina that develops chromatin mapping assays, nucleosome reagents, and bioinformatics tools for epigenetics research, serving academic, pharmaceutical, and biotech customers globally through direct sales and distributor partnerships.
Ownership category
akta.pro rank

EpiCypher industry classification

Industry
Product category
Epigenetics Research Tools
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAGANAF
Epigenomics & Chromatin Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Chromatin mapping kits
  • Epigenetics research tools
  • DNA methylation assays
  • Recombinant nucleosome products
  • Chromatin profiling reagents

Where EpiCypher is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

EpiCypher business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales - Kits and Reagents: Sale of chromatin mapping assay kits, nucleosome products, antibodies, and reagents directly through the company website and via international distributors
  2. Custom Services: Laboratory services including CUTANA CUT&RUN Services, Fiber-seq Assay Services, DNA Methylation Sequencing Services, and Custom Nucleosome Development Services
  3. Cloud Bioinformatics Credits: Pay-as-you-go credits for CUTANA Cloud data analysis platform, with tiered pricing based on volume

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCUTANA Fiber-seq Kit - 8 Reactions: $695.00, 24 Reactions: $1,795.00
Unit PricingPay-as-you-goCUTANA CUT&Tag Kit v4 - 24 Reactions: $1,295.00, 48 Reactions: $2,395.00
Unit PricingPay-as-you-gomeCUT&RUN Kit for DNA Methylation Sequencing: $685.00 (24 reactions)
Usage-basedPay-as-you-goCUTANA Cloud: $25 per credit (introductory), $20-$40 standard pricing
Unit PricingPay-as-you-goCUT&RUN Kits: $595-$945; SNAP-CUTANA K-MetStat Panel: $325; Antibodies: $110-$545
Unit PricingPay-as-you-goRecombinant Nucleosomes: $425-$575; Designer Nucleosomes (dNucs): $525-$575

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

EpiCypher product offering

Product offering

Core offering

EpiCypher develops, manufactures, and sells proprietary kits, reagents, and assays for chromatin mapping and epigenomics research, including CUTANA CUT&RUN, CUT&Tag, Fiber-seq, and meCUT&RUN kits, over 190 recombinant and modified nucleosome products, SNAP spike-in controls, SNAP-certified antibodies, and the CUTANA Cloud bioinformatics platform. The company also offers fee-for-service laboratory execution for chromatin profiling and custom nucleosome development.

Product overview

EpiCypher offers a comprehensive portfolio of epigenetics research products centered on the CUTANA platform, including CUTANA CUT&Tag Kits (v4), CUTANA CUT&RUN Kits and Assays, Fiber-seq Kits for long-read sequencing, meCUT&RUN DNA Methylation Sequencing Kits, and Multiomic CUT&RUN assays. The company provides over 190 unique nucleosome products including recombinant, modified, mutant, and cell-derived nucleosomes with defined PTMs. Additional offerings include SNAP-Certified Antibodies, SNAP Spike-in Controls, EpiDyne Chromatin Remodeling Assays, and the CUTANA Cloud bioinformatics platform. EpiCypher also provides laboratory services including CUT&RUN Services, Fiber-seq Assay Services, DNA Methylation Sequencing Services, Custom Nucleosome Development, Captify Assay Services, and an FFPE Grant Program. The products work together as an integrated ecosystem where CUT&Tag and CUT&RUN assays generate data analyzed by CUTANA Cloud, while spike-in controls and nucleosomes enable workflow optimization and validation.

Differentiator

Problem solved

Functional benefit

Brands

  • CUTANA: CUTANA is EpiCypher's flagship platform for chromatin mapping assays including CUT&RUN and CUT&Tag technologies.
  • EpiDyne
  • SNAP-CUTANA
  • Captify
  • CUTANA Cloud

Products and services

  • CUTANA CUT&Tag Kit Complete solution for ultra-sensitive mapping of histone post-translational modifications featuring direct-to-PCR protocol, pAG-Tn5 tagmentation, and all reagents from cells to sequencing libraries.
  • CUTANA CUT&RUN Assays

Quantifiable outcome

  • 80% DNA methylation capture with input as low as 10,000 cells using meCUT&RUN
  • +3 more outcomes

Companies that use EpiCypher

Customer profile

Segments2 records

Ideal customer profiles2 records

EpiCypher technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature6 records

EpiCypher partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • New England Biolabs (NEB)coreChannel Partner/ Reseller/ Distributor · 19 May 2026Expanded strategic partnership where NEB distributes EpiCypher's genomic products in international markets. Partnership builds on prior collaboration and focuses on developing innovative technologies for gene regulation, chromatin biology, and disease mechanisms.
  • Altius Institute for Biomedical SciencescoreTechnology or Integration · 12 November 2025EpiCypher licensed Fiber-seq technology from the Altius Institute for Biomedical Sciences. This exclusive licensing arrangement provides EpiCypher rights to commercialize the breakthrough single-molecule chromatin mapping technology.
  • Pacific Biosciences (PacBio)coreTechnology or Integration · 14 October 2025Partnership announced alongside PacBio's Revio and Vega platform innovations to expand sample preparation and chromatin analysis capabilities. EpiCypher's Fiber-seq and chromatin mapping products integrate with PacBio's long-read sequencing platforms for enhanced epigenomics research.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

EpiCypher competitors and assessment

Company assessment

Direct peers

  • Active Motif: Active Motif is a direct competitor in chromatin and epigenetics research kits, including CUT&RUN and ChIP-seq reagents, antibodies, and nucleosomes sold to the same academic and pharma customer base as EpiCypher.
  • Diagenode: Diagenode offers CUT&RUN and CUT&Tag kits, antibody portfolios, and epigenetics services that directly compete with EpiCypher's CUTANA franchise, serving overlapping academic and translational customers.
  • Cell Signaling Technology: CST provides CUT&RUN-validated antibodies and is a direct competitor in histone PTM reagents and chromatin profiling consumables, with overlapping SNAP-Certified-style antibody validation use cases.
  • Zymo Research: Zymo Research sells DNA methylation and epigenetics kits (e.g., bisulfite conversion, Methylated DNA IP) that compete with EpiCypher's meCUT&RUN offering for the same DNA methylation research budgets.

Broad incumbents

  • New England Biolabs: NEB is both EpiCypher's international distribution partner and a broad incumbent in molecular biology reagents and enzymes, offering overlapping capabilities in nucleic acid processing and chromatin research tools.
  • Abcam: Abcam is a broad incumbent supplying antibodies and reagent kits including histone PTM antibodies used in CUT&RUN/CUT&Tag, competing with EpiCypher's SNAP-Certified Antibody line for the same research budgets.
  • Millipore Sigma: MilliporeSigma supplies a broad catalog of life science reagents, nucleosomes, and antibodies used in chromatin research, providing overlapping but less specialized offerings compared to EpiCypher's curated epigenetics portfolio.
  • Thermo Fisher Scientific: Thermo Fisher offers broad life sciences reagents, instruments, and bioservices including chromatin immunoprecipitation and methylation products that compete indirectly with EpiCypher's kit and service portfolio.

Emerging players

  • Watchmaker Genomics: Watchmaker Genomics is an emerging player in DNA sequencing library prep and molecular biology reagents with partial overlap to EpiCypher's library prep and enzyme product lines.
  • 10x Genomics: 10x Genomics provides single-cell ATAC and multiome chromatin accessibility assays that serve the same single-cell chromatin profiling customer base as EpiCypher's CUTANA-based assays, representing an adjacent emerging competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

EpiCypher social profiles

Digital presence

EpiCypher financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EpiCypher leadership team

Management profile

Number of profiles

Profiles7 records

EpiCypher funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EpiCypher M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiCypher

What does EpiCypher do?

EpiCypher develops, manufactures, and sells proprietary kits, reagents, and assays for chromatin mapping and epigenomics research, including CUTANA CUT&RUN, CUT&Tag, Fiber-seq, and meCUT&RUN kits, over 190 recombinant and modified nucleosome products, SNAP spike-in controls, SNAP-certified antibodies, and the CUTANA Cloud bioinformatics platform. The company also offers fee-for-service laboratory execution for chromatin profiling and custom nucleosome development.

Is EpiCypher a public or private company?

EpiCypher is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was EpiCypher founded?

EpiCypher was founded in 2012. It employs 11 to 50 people.

Where is EpiCypher based?

EpiCypher is headquartered in Durham, United States, in the North America region.

How does EpiCypher make money?

Three revenue lines are on record. Product Sales - Kits and Reagents are the primary driver. The others are custom Services and cloud Bioinformatics Credits.

Who are EpiCypher's main competitors?

Direct peers on record are Active Motif, Diagenode, Cell Signaling Technology and Zymo Research. Broad incumbents are New England Biolabs, Abcam, Millipore Sigma and Thermo Fisher Scientific. Emerging players are Watchmaker Genomics and 10x Genomics.

Does EpiCypher have an API?

No public API is recorded for EpiCypher.

What industry is EpiCypher in?

EpiCypher's product category is Epigenetics Research Tools. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEpiCypher and New England Biolabs Expand Strategic Partnership to Advance Epigenomics ResearchEpiCypher and New England Biolabs announced an expanded strategic partnership to develop epigenomics research tools, building on their prior collaboration. The partnership focuses on creating innovative technologies for gene regulation, chromatin biology, and disease mechanisms, with NEB distributing EpiCypher's genomic products in international markets.EIN PresswireDNA Methylation Market to Reach USD 7.7 Bn by 2036, Driven by Precision Oncology and Liquid Biopsy Advancements - TMRTransparency Market Research published a market outlook report projecting the global DNA methylation market to grow from US$ 1.9 billion in 2025 to US$ 7.7 billion by 2036, representing a 13.5% CAGR. North America led the market with 42.3% revenue share in 2025, while Kits & Reagents dominated product categories at 43.7%. The report highlights precision oncology, liquid biopsy advancements, and NGS innovation as primary growth drivers, with recent company activities including YD Bio Limited's merger MoU with EG BioMed, Illumina's 5-base solution launch, and EpiCypher's CUTANA product releases.Manufacturing ChemistAbcam and EpiCypher partner to develop ChIC/CUT&RUN reagentsAbcam and EpiCypher have announced a partnership to co-develop improved reagents for ChIC/CUT&RUN applications, combining Abcam's antibody characterization methods with EpiCypher's platform. This collaboration aims to enhance the reproducibility of epigenomic data and accelerate research in gene regulation and precision medicine. Abcam has already integrated EpiCypher-generated data into its validation approach to ensure higher confidence in reagent performance.PacbHow pairing EpiCypher’s Fiber-seq with HiFi sequencing delivers an all-in-one multiomic viewEpiCypher launched the CUTANA Fiber-seq kit, a new tool designed to work with PacBio HiFi sequencing to provide a unified view of chromatin structure and gene regulation. This multiomic assay allows researchers to profile DNA sequence, methylation, accessibility, and protein interactions in a single workflow without PCR or antibodies. The technology aims to overcome limitations of traditional short-read methods by offering high-resolution insights into complex genomic regions.PharmiWeb.comEpiCypher Launches Fiber-seq Kit to Democratize Single-Molecule Chromatin MappingEpiCypher announced the launch of its CUTANA Fiber-seq Kit for single-molecule chromatin mapping, accompanied by an exclusive licensing agreement for Fiber-seq technology from the Altius Institute for Biomedical Sciences. The kit provides all essential reagents for the complete Fiber-seq workflow and is compatible with both PacBio and Oxford Nanopore Technologies sequencing platforms. EpiCypher and PacBio are collaborating to help researchers adopt Fiber-seq by combining chromatin biochemistry with long-read sequencing, with early enthusiasm from the long-read sequencing community.YahooPACB Partners With EpiCypher to Advance Epigenomics Using Fiber-SeqPacBio partnered with EpiCypher to advance epigenomics using Fiber-Seq, combining long-read sequencing with chromatin biology expertise. The collaboration introduces the CUTANA Hia5 enzyme for single-molecule chromatin analysis. PacBio shares closed flat at $1.24, down 32.3% year-to-date, while the epigenetics market is projected to grow from $14.63B to $39.15B by 2030.GlobeNewswirePacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq WorkflowPacBio and EpiCypher announced a partnership bringing EpiCypher's CUTANA Hia5 enzyme to Fiber-seq assays on PacBio HiFi sequencing systems. The enzyme is commercially available in 8 and 24 reaction formats, enabling single-molecule chromatin biology insights. The collaboration aims to advance PacBio's role in epigenomics.GenengnewsDNA Methylation Sequencing More Affordable Without Compromising ResultsEpiCypher has introduced CUTANA™ meCUT&RUN, a novel assay designed to provide cost-effective and sensitive profiling of DNA methylation across the genome. The method utilizes a GST-tagged methylation-binding domain to enrich methylated DNA, achieving performance comparable to whole-genome sequencing with significantly lower read requirements (20–50 million reads) and reduced input needs.PR NewswireEpiCypher Expands Exclusive Licensing Agreement to Advance CUT&Tag TechnologyEpiCypher announced an exclusive licensing agreement with Fred Hutch Cancer Center for CUT&Tag technology IP, including CUTAC, RT&Tag, and CUT&Tag-FFPE. The technologies enable high-sensitivity chromatin profiling, single-cell, and spatial studies, and compatibility with formalin-fixed paraffin-embedded samples. EpiCypher plans to integrate these into its product offerings.SecSEC FORM DEpicypher, Inc. filed a Form D with the U.S. Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates a total offering amount of $3,300,000 USD for equity securities, with proceeds designated for working capital. The first sale date was recorded as June 27, 2024, and one investor has already participated in the offering.